Pharma Mirror Magazine

The AMG 510 model binding the KRAS which is mutant. Binding is irreversible, hindrance constant is viable (nanomolar) in pharmacodynamics terms. Be that as it may, it's effectiveness should be demonstrated clinically. One day this synthetic compound may hit the market and become popular among cancer patients.

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

March 8, 2021

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against

Pharmaceutical News

I Holland Announces a New Leadership Team

March 3, 2021

I Holland, leaders in the manufacture of tablet tooling for the pharmaceutical and nutraceutical markets, has announced a series of

Pharmaceutical News

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

March 2, 2021

Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered

Pharmaceutical News

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

March 1, 2021

Novartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of

Pharmaceutical Articles

Accelerating Investigator Recruitment with NLP

March 1, 2021

NLP and social graphs are effective instruments to speed up investigator recruitment and ensure timely pharmaceutical product releases. Read how

Pharmaceutical News

New Sales Directors at Romaco in Cologne, Bologna and Karlsruhe

February 26, 2021

Borja Guerra has been appointed new Sales & Service Director of Romaco Kilian in Cologne. The Romaco facilities in Bologna

MORE NEWS

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

I Holland Announces a New Leadership Team

New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong

Novartis Piqray(R) – First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval

Accelerating Investigator Recruitment with NLP

New Sales Directors at Romaco in Cologne, Bologna and Karlsruhe